Cited by 141Nicotinic Acetylcholine Receptors StudySmoking Behavior and CessationCancer, Stress, Anesthesia, and Immune Response

Activated Cholinergic Signaling Provides a Target in Squamous Cell Lung Carcinoma

Open access
Song, Pingfang, Sekhon, Harmanjatinder S., Fu, Xiao Wen, Maier, Michelle, Jia, Yibing, Duan, Jie, Proskosil, Becky J., Gravett, Courtney +4 more·2008·Cancer Research

Published version of a preprint

Abstract

The binding of exogenous nicotine to nicotinic acetylcholine (ACh) receptors (nAChR) and the binding of endogenous ACh to both nAChR and muscarinic ACh receptors (mAChR) stimulate growth of both small cell and non–small cell lung carcinomas. Understanding how cholinergic signaling is up-regulated in lung cancer may suggest new therapeutic approaches. Analysis of 28 squamous cell lung carcinomas (SCC) showed increased levels of α5 and β3 nAChR mRNA and increased levels of ACh associated with increased levels of choline acetyltransferase mRNA and decreased cholinesterase mRNAs. Lynx1, an allosteric inhibitor of nAChR activity, was also decreased in SCC. Thus, cholinergic signaling is broadly increased in SCC caused by increased levels of receptors, increased levels of ligands, and decreased levels of receptor inhibitors. Partially explaining the cholinergic up-regulation seen in SCC, incubation of the H520 SCC cell line with nicotine increased levels of ACh secretion, increased expression of nAChR, and, as measured by electrophysiologic recording, increased activity of the expressed nAChR. Consistent with these effects, nicotine stimulated proliferation of H520 cells. One approach to blocking proliferative effects of nicotine and ACh on growth of lung cancers may be through M3 mAChR antagonists, which can limit the activation of mitogen-activated protein kinase that is caused by both nicotinic and muscarinic signaling. This was tested with the M3-selective muscarinic antagonist darifenacin. Darifenacin blocked nicotine-stimulated H520 growth in vitro and also blocked H520 growth in nude mice in vivo. Thus, cholinergic signaling is broadly up-regulated in SCC and blocking cholinergic signaling can limit basal and nicotine-stimulated growth of SCC. [Cancer Res 2008;68(12):4693–700]

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-08-0183

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Song, P., Sekhon, H. S., Fu, X. W., Maier, M., Jia, Y., Duan, J., Proskosil, B. J., Gravett, C., Lindstrom, J., Mark, G. P., Saha, S., & Spindel, E. R.
Affiliations
  • Oregon National Primate Research Center (US)
  • 1Division of Neuroscience, Oregon National Primate Research Center, Oregon Health and Sciences University, Beaverton, Oregon;
  • University of Pennsylvania (US)
  • Oregon Health & Science University (US)
  • Novartis (Switzerland) (CH)
Venue
Cancer Research
Published
2008-06-15
Volume
68
Issue
12
Pages
4693-4700
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2047735189
Cited by
141
References
51
Citations by year
2026: 2 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 11 · 2021: 12 · 2020: 6 · 2019: 4 · 2018: 3 · 2017: 4 · 2016: 7 · 2015: 10 · 2014: 7 · 2013: 10 · 2012: 12
FWCI
4.52
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cancer Research (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Heart, Lung, and Blood Institute (HL087710, R01HL087710)
  • National Institute of Neurological Disorders and Stroke (NS11323, R01NS011323)
  • National Center for Research Resources (P51RR000163, K01RR000163, RR-00163.)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Psychiatry and Mental health › Cancer, Stress, Anesthesia, and Immune Response
Keywords
lung squamous cell carcinoma, cholinergic neurotransmission, nicotinic acetylcholine receptors, muscarinic receptors, choline acetyltransferase, cholinesterase, Lynx1, nicotine, acetylcholine, M3 muscarinic receptor antagonist, darifenacin, mitogen-activated protein kinase, cell proliferation
MeSH terms
Acetylcholine, Animals, Benzofurans, Calcium, Carcinoma, Squamous Cell, Cells, Cultured, Choline O-Acetyltransferase, Electrophysiology, Humans, Lung, Lung Neoplasms, Male, Membrane Glycoproteins, Mice, Nude, Nicotine, Phosphorylation, Pyrrolidines, Receptors, Nicotinic, RNA, Messenger, Blotting, Western, Signal Transduction, Muscarinic Antagonists, Reverse Transcriptase Polymerase Chain Reaction, Receptor, Muscarinic M3, Adaptor Proteins, Signal Transducing, Cell Proliferation, Vesicular Acetylcholine Transport Proteins, Mice, GPI-Linked Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review